Clinical trial investigators and their prescribing patterns: Another dimension to the relationship between physician investigators and the pharmaceutical industry

JAMA

Volumn 295, Issue 23, 2006, Pages 2787-2790

  Psaty, Bruce M ^a   Rennie, Drummond ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; ANTIHYPERTENSIVE AGENT; SEROTONIN UPTAKE INHIBITOR;

ASTHMA; CLINICAL RESEARCH; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG INDUSTRY; DRUG RESEARCH; EDITORIAL; EVIDENCE BASED MEDICINE; FUNDING; HEART INFARCTION; HUMAN; HYPERTENSION; MEDICAL PRACTICE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SUICIDE; UNITED KINGDOM;

EID: 33745275220     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.295.23.2787     Document Type: Editorial

References (34)

1. Chobanian AV, Bakris GL, Black HR, et al; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC7 report. JAMA. 2003;289:2560-2572.
2. Psaty BM, Manolio TA, Smith NL, et al. Time trends in high blood pressure control and the use of antihypertensive medications in older adults: the Cardiovascular Health Study. Arch Intern Med. 2002;162:2325-2332.
3. Fretheim A, Oxman AD. International variation in prescribing antihypertensive drugs: its extent and possible explanations. BMC Health Serv Res. 2005;5:21.
4. Kessler DA, Rose JL, Temple RJ, Schapiro R, Griffin JP. Therapeutic-class wars-drug promotion in a competitive marketplace. N Engl J Med. 1994;331:1350-1353.
5. Andersen M, Kragstrup J, Søndergaard J. How conducting a clinical trial affects physicians' guideline adherence and drug preferences. JAMA. 2006;295:2759-2764.
6. Rennie D. Trial registration: a great idea switches from ignored to irresistible. JAMA. 2004;292:1359-1361.
7. DeAngelis CD, Drazen JM, Frizelle FA, et al. Clinical trial registration: a statment from the Internaltional Committee of Medical Journal Editors. JAMA. 2004;292:1363-1364.
8. DeAngelis CD, Drazen JM, Frizelle FA, et al. Is this clinical trial fully registered? a statement from the International Committee of Medical Journal Editors. JAMA. 2005;293:2927-2929.
9. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283:373-380.
10. Chew LD, O'Young TS, Hazlet TK, Bradley KA, Maynard C, Lessler DS. A physician survey of the effect of drug sample availability on physicians' behavior. J Gen Intern Med. 2000;15:478-483.
11. Katz D, Caplan AL, Merz JF. All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift-giving. Am J Bioeth. 2003;3:39-46.
12. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA. 2003;290:252-255.
13. Blumenthal D. Doctors and drug companies. N Engl J Med. 2004;351:1885-1890.
14. Brennan TA, Rotherman DJ, Blank L, et al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA. 2006;295:429-433.
15. Lexchin J, Bero LA, Bjulbegovic B, Clark O. Pharmaceutical industry sponsorship and research: outcome and quality: systematic review. BMJ. 2003;326:1167.
16. Kjaergard LL, Als-Nielsen B. Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trial published in BMJ. BMJ. 2002;325:249-252.
17. Chaudhry S, Schroroter S, Smith R, Morris J. Does declaration of competing interests affects readers' perceptions? a randommised trial. BMJ. 2002;325:1391-1392.
18. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine-selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 2003;326:1171.
19. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA. 2003;290:921-928.
20. Curfman GD, Morrissey S, Drazen JM. Expression of concern: Bombardier et al, "comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis." N Engl J Med. 2000;343:1520-1528.
21. N Engl J Med. 2005;353:2813-2814.
22. Healy D, Cattell D. Interface between authorship, industry, and science in the domain of therapeutics. Br J Psychiatry. 2003;183:22-27.
23. Curfman GD, Morrissey S, Drazen JM. Expression of concern reaffirmed [published online ahead of print February 22, 2006]. N Engl J Med. 2006;354:1193.
24. Pfizer Inc. A double-blind randomized placebo-controlled comparative study of celecoxib (SC-58635) for the inhibition of progression of Alzheimer's Disease, protocol IQ5-97-02-001. http://www.clinicalstudyresults.org/documents/ company-study_76_0.pdf. Accessed January 29, 2005.
25. Johansen HK, Gotzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA. 1999;282:1752-1759.
26. Rennie D, Luft HS. Pharmacoeconomic analyses: making them transparent, making them credible. JAMA. 2000;283:2158-2160.
27. Pena E. The value of phase IV postmarketing research. PharmaVoice, December 2003. http://www.lifetreeclinical.com/web_files/1203phase4.pdf. Accessibility verified May 25, 2006.
28. Studdert DM, Mello MM, Brennan TA. Financial conflicts of interest in physicians relationships with the pharmaceutical industry self-regulation in the shadow of federal prosecution. N Engl J Med. 2004;351:1891-1900.
29. Department of Health and Human Services; Office of the Inspector General. OIG compliance program guidance for pharmaceutical manufacturers. Fed Regist. 2003;68:23731-23743.
30. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
31. Psaty BM, Weiss NS, Furberg CD. Recent trials in hypertension: compelling science or commercial speech? JAMA. 2006;295:1704-1706.
32. Psaty BM, Rhoads C, Furberg CD. Evidence-based medicine: worship of form and treatment of high blood pressure [editorial]. J Gen Intern Med. 2000;15:755-756.
33. Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
34. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.